Search Clinical Trials in the European Union

6-12 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
101-120 of 397 trials

Dupuytren's Contracture: Bacterial Collagenase Treatment

We are studying a new bacterial collagenase injection for patients with Dupuytren's contracture to see if it improves hand function and reduces contracture compared to a placebo.

Dupuytren's Contracture6-12 monthsSafety phase (I)Efficacy phase (II)11-15 visitsInvestigational MedicinesOrthopedics and TraumatologyRheumatology

Pancreatic Cancer: Testing Enzyme Therapy

We are studying whether pancreatic enzyme replacement therapy can help patients with unresectable pancreatic cancer gain weight and improve their nutrition. This may enhance their quality of life and ability to handle chemotherapy.

Pancreatic Exocrine Insufficiency6-12 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteGastroenterologyOncology

Thalassemia and Myelodysplastic Syndromes: SP-420 Treatment Study

We are investigating a new treatment, SP-420, for individuals with transfusion-dependent thalassemia or low-risk myelodysplastic syndromes. The study aims to find the right dose and evaluate its effectiveness in reducing excess iron and its safety.

Thalassemia and Myelodysplastic Syndromes6-12 monthsEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematology

Statin Intolerance: Personalized Treatment Study

We are exploring whether personalized treatment plans can help people who struggle with statin medications. The goal is to improve their cholesterol management while minimizing side effects.

High Cardiovascular RiskStatin Intolerance6-12 monthsMonitoring phase (IV)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Acute Myeloid Leukemia: Venetoclax Treatment Study

We are studying whether adding venetoclax to standard chemotherapy helps adults with newly diagnosed acute myeloid leukemia live longer and achieve better treatment results. This trial compares venetoclax to a placebo to assess its impact on patient outcomes.

Acute Myeloid Leukemia6-12 monthsConfirmation phase (III)Standard MedicinesHematology

Moderate Acne: Oral Isotretinoin vs. Standard Care

We are comparing a new oral medication to standard treatments for moderate acne in patients with skin of color. Our goal is to see if this new approach improves acne severity and quality of life.

Acne6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesDermatology

Hepatitis B: TherVacB Vaccine Study

We are testing a new vaccine for adults with hepatitis B to see if it is safe and how well it boosts the immune response. The study will also check if it helps reduce the virus in the body.

Chronic Hepatitis B6-12 monthsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesHepatologyInfectious Diseases

Chronic Lymphocytic Leukemia: Pirtobrutinib vs. Ibrutinib

We are comparing the effectiveness of pirtobrutinib to ibrutinib in patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. This study also focuses on those who are newly diagnosed and have a specific genetic change.

Chronic Lymphocytic Leukemia6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Axial Spondyloarthritis: Risankizumab Treatment

We are studying the effects of a new treatment for patients with very early axial spondyloarthritis. The goal is to see if it can reduce disease activity and improve overall function.

Axial Spondyloarthritis6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesRheumatology

Satralizumab for Pediatric Neuromyelitis Optica Spectrum Disorder

We are studying how well satralizumab works and its safety in children aged 2-11 with AQP4 antibody positive neuromyelitis optica spectrum disorder. This research aims to improve treatment options for these young patients.

Neuromyelitis Optica Spectrum Disorder (NMOSD)6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesNeurologyPediatrics

Mpox Vaccination Study: MPOX-VAX

We are studying a vaccine to see how well it prevents Mpox infection and how long the immune response lasts. Participants will also be monitored for other infections to understand overall health impacts.

Mpox Infection6-12 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious Diseases

Systemic Juvenile Idiopathic Arthritis: Baricitinib Study

We are studying the effectiveness of baricitinib in children aged 1 to under 18 with systemic juvenile idiopathic arthritis. This research aims to find out if it helps improve their condition.

Systemic Juvenile Idiopathic Arthritis6-12 monthsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemotePediatricsRheumatology

Isatuximab for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

We are studying whether Isatuximab can safely help adults with relapsed or refractory T-cell acute lymphoblastic leukemia achieve remission. This trial looks at its effects alone and with other chemotherapy drugs.

T-cell Acute Lymphoblastic Leukemia6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Meningococcal Vaccine Study for Infants and Toddlers

We are investigating a new meningococcal vaccine to see how well it works and its safety compared to an existing vaccine in healthy infants and toddlers. This study focuses on children receiving their first doses at 6-7 months and a booster at 12-13 months.

Meningococcal Infection6-12 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInfectious DiseasesPediatrics

Systemic Lupus Erythematosus: Dapirolizumab Pegol Study

We are studying whether dapirolizumab pegol can improve symptoms in people with moderately to severely active systemic lupus erythematosus. This trial will also assess the safety of this new treatment when added to standard care.

Systemic Lupus Erythematosus6-12 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Meningococcal B Vaccine for Adults with Asplenia

We are studying the safety and immune response of the BEXSERO® vaccine in adults without a spleen. This trial compares their response to healthy individuals to ensure effective protection against meningococcal disease.

Splenectomy6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesInternal Medicine

Advanced Solid Tumors: GTAEXS617 Treatment Study

We are testing a new treatment called GTAEXS617 for patients with advanced solid tumors to see how safe it is and whether it can help fight the cancer. This study will look at the treatment alone and with standard therapies.

Ovarian Epithelial CancerColorectal AdenocarcinomaNon-Small Cell Lung Cancer6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

MDMA-Assisted Therapy for Treatment-Resistant PTSD

We are studying whether MDMA-assisted therapy can improve symptoms of PTSD in individuals who have not responded to other treatments. This trial also looks at how well this therapy works in a hospital setting.

Posttraumatic Stress Disorder6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemotePsychiatry

Dextroamphetamine for Amphetamine Dependence: A Clinical Trial

We are studying whether daily prescribed dextroamphetamine can help reduce illicit amphetamine use in adults with amphetamine and opioid dependencies. The trial also looks at its effects on mental health, physical health, and overall quality of life.

Comorbid Dependencies to Amphetamines and Opioids6-12 monthsEfficacy phase (II)Standard MedicinesPsychiatry

Inflammatory Bowel Disease: Adalimumab-680LT Study

We are investigating the safety and imaging of a new version of adalimumab for people with inflammatory bowel diseases. This study aims to see how well the drug targets inflammation and its potential effects on health.

Inflammatory Bowel Disease (IBD)6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesGastroenterologyInfectious Diseases